Agios and Alnylam sign agreement for siRNA candidate

[Manouche]

 « We are pleased to license this programme from Alnylam, the leading RNAi therapeutics company, with the goal of delivering a convenient, disease-modifying treatment option that addresses the underlying pathophysiology of PV and reduces or eliminates the need for phlebotomy.

“We look forward to initiating IND-enabling studies this year with the aim of delivering a transformative treatment option for this patient community with profound unmet need.”

pharmaceutical-business-rev...

[Steve_Essex]

thanks for sharing!! Do we know much on the specifics for how the RNA tech works?… haven’t seen this come up from searches I’ve been doing over the last year or so on emerging treatments…

[Steve_Essex in reply to Steve_Essex]

Ignore… just seen the other very detailed post and discussions!!!